Nature:CRISPR技术又有新突破!

2015-07-01 佚名 生物谷

来自哈佛医学院和麻省总医院的研究者们在最新一期Nature杂志上发表了他们新改进的CRISPR-Cas9技术,识别序列的范围更大,识别也更为精准。文章第一作者Benjamin Kleinstiver介绍说新技术里的Cas9变种可以识别那些野生型Cas9无法修饰的人类和斑马鱼基因的位点,这使得CRISPR技术在多变的基因组里识别范围大大增加。CRISPR-Cas9核酸酶由Cas9蛋白和20个核苷酸长

来自哈佛医学院和麻省总医院的研究者们在最新一期Nature杂志上发表了他们新改进的CRISPR-Cas9技术,识别序列的范围更大,识别也更为精准。文章第一作者Benjamin Kleinstiver介绍说新技术里的Cas9变种可以识别那些野生型Cas9无法修饰的人类和斑马鱼基因的位点,这使得CRISPR技术在多变的基因组里识别范围大大增加。

CRISPR-Cas9核酸酶由Cas9蛋白和20个核苷酸长的RNA分子组成。Cas9蛋白负责切断DNA双链,RNA分子用于识别目标序列,不过在目标序列旁边还要有可以被Cas9识别的protospacer adjacent motif (PAM)才能让酶发挥作用。实验室里通常使用的SpCas9来自于细菌Streptococcus pyogenes,它所需要的PAM序列一般为NGG形式,这在某种程度上限制了Cas9使用的范围。

为了克服这一限制,该研究组建立了一套工程化系统,用进化研究的方法,从大量随机突变的SpCas9变种中找到了可以识别新PAM序列的突变组合。这些新的Cas9变种将序列识别的范围扩大了两倍。同时他们还发现了一个SpCas9变种可以减少基因编辑里的脱靶问题。此外,研究人员还在细菌Streptococcus thermophiles和Staphylococcus aureus里发现了两个较小的Cas9直系同源蛋白St1Cas9和SaCas9。

文章的通讯作者Joung表示, 他们的新发现应该对所有使用Cas9的研究人员有所帮助,另外他认为此研究更重要的意义在于,他们首次证实SpCas9可以用定向蛋白质进化的方法改进,他们相信利用类似的方法还可以改进Cas9酶其他的特点来满足更多的需要。麻省总医院已经为文章中的SpCas9申请了专利。

原始出处:

Benjamin P. Kleinstiver, Michelle S. Prew, Shengdar Q. Tsai, Ved V. Topkar, Nhu T. Nguyen, Zongli Zheng, Andrew P. W. Gonzales, Zhuyun Li, Randall T. Peterson, Jing-Ruey Joanna Yeh, Martin J. Aryee & J. Keith Joung.Engineered CRISPR-Cas9 nucleases with altered PAM specificities.Nature, June 22, 2015.doi:10.1038/nature14592

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
    2015-11-09 zxxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
    2016-01-13 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
    2015-07-03 yuandd
  5. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1724885, encodeId=8ab71e24885e6, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Nov 09 11:07:00 CST 2015, time=2015-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880713, encodeId=276a1880e13f8, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jan 13 20:07:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30580, encodeId=024430580a4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:25:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275837, encodeId=c45d12e5837e7, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618689, encodeId=aa96161868902, content=<a href='/topic/show?id=e798524076' target=_blank style='color:#2F92EE;'>#Crispr技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5240, encryptionId=e798524076, topicName=Crispr技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a49419938232, createdName=ms1779634646866130, createdTime=Fri Jul 03 04:07:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30166, encodeId=76e730166d2, content=发展越来越迅速。, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Jul 01 21:18:00 CST 2015, time=2015-07-01, status=1, ipAttribution=)]
    2015-07-01 medcardio

    发展越来越迅速。

    0

相关资讯

Nat Biotechnol:光控基因编辑CRISPR/Cas9系统问世

日本的科学家们已经开发出一种光活化的Cas9核酸酶来控制CRISPR诱导的基因编辑,一个“开关”即可激活。这个光激活的Cas9核酸酶可以为研究者在RNA诱导的核酸酶研究上提供更大的空间和时间的控制。这篇研究在线发表在最新的Nature Biotechnology中。 来自加州大学的干细胞生物学家Paul Knoepfler评论这项研究时表示:“这是一种非常有效的新系统,通过光精确地控制基因编

全新基因编辑技术引发研究领域巨变

美国旧金山格莱斯顿研究所遗传学家Bruce Conklin一直试图找到DNA变异如何影响不同的人类疾病,但使用的工具有些笨重。当他研究来自病人的细胞时,很难知道哪个序列对疾病来说很重要,哪些只是背景噪音。同时,将突变植入细胞是一项昂贵且费力的工作。 2012年,他通过阅读了解到一项最新发表的、被称为CRISPR的技术。它能使研究人员快速改变几乎任何生物体的DNA,包括人类。此后不

PNAS:用CRISPR解决世界性难题

近年来致病菌的抗生素抗性越演越烈,这已经成为了一个世界性的难题。科学家们日前在CRISPR技术的基础上,开发了一个双噬菌体系统,能够使耐药菌敏感化,并且有选择的杀死它们。这项研究发表在五月十八日的美国国家科学院院刊PNAS杂志上。传统的噬菌体疗法是用一种或多种噬菌体去感染和裂解相应的细菌菌株。不过,把噬菌体递送到被感染的组织还存在一定的困难。Tel Aviv大学Udi Qimron等人开发的这种改

CRISPR、RNAi、TALEN一张图教你做出正确选择

研究基因功能最常见的方法是,减少或者阻断基因表达,然后进行表型分析。十多年来,RNAi一直是这一领域的王者,然而新兴技术的涌现(尤其是CRISPR技术)正在逐渐瓦解RNAi的统治地位。日新月异的技术发展为生物学研究提供了越来越大的助力,也给研究者们带来了一个有些纠结的问题,“到底应该选择那一种技术呢”。  1998年Andrew Fire 和Craig Mello两位科学家首次

CRISPR技术剪掉HIV病毒基因,根治艾滋病

艾滋病病毒是一种高效且多变的逆转录病毒。一旦病毒将其DNA插入宿主细胞的基因组,它即拥有很长的潜伏期,可以保持休眠和隐匿状态达数年之久。 虽然医生可以通过多种不同的抗逆转录病毒药物搭配使用的鸡尾酒疗法来控制病毒,但若停止治疗,病毒即可恢复活力。 为了使潜伏中的艾滋病病毒失活,马萨诸塞大学医学院(University of Massachusetts Medical School

Nature:再掀学术伦理之争!中国科学家瞄准人类胚胎基因改造

中国科学家走在世界的第一位,首次报道成果对人类胚胎的基因进行改造。该项研究结果在线发表在最新一期 Protein & Cell 杂志上。这一消息正式确认了科学界关于对人类胚胎基因研究工作正在开展的谣言,而后者因伦理问题在上个月引起了激烈的讨论。 在这项由中山大学基因功能学教授Jun-jiu Huang所主持的研究中,研究人员利用来自当地生殖医疗机构“不能存活”的胚